A week after finishing pivotal trials with its nausea drug, Hana Biosciences Inc. signed a letter of intent to double its pipeline of compounds by licensing worldwide rights to three targeted chemotherapeutics from Inex Pharmaceuticals Corp. in a stock-and-cash deal worth up to $42 million. (BioWorld Today)
No Abstract West Coast EditorCerus Corp. priced its public offering of 4.5 million shares at $8.75 per share for proceeds of about $39.4 million, and the company expects to net about $36.9 million after expenses, or $42.5 million if the underwriters exercise their option to buy 675,000 more shares.The company’s shares (NASDAQ:CERS) closed Thursday at $8.75, down 46 cents.
Mixed interim data from a pair of Phase II trials with its drug for hepatitis C virus sent Human Genome Sciences Inc.’s stock down 20.3 percent. (BioWorld Today)
About a year after its deal for the compound ended with Bayer AG, Paratek Pharmaceuticals Inc. entered a license and development deal with Merck & Co. Inc. worth up to $127 million plus royalties if the FDA approves PTK 0796, a broad-spectrum antibiotic with oral and intravenous versions in Phase I clinical trials. (BioWorld Today)
